

Thierry Lave

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11620332/publications.pdf>

Version: 2024-02-01

41
papers

2,950
citations

159585

30
h-index

276875

41
g-index

46
all docs

46
docs citations

46
times ranked

2021
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics. Clinical Pharmacokinetics, 2006, 45, 511-542.	3.5	301
2	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessment of prediction methods of human clearance. Journal of Pharmaceutical Sciences, 2011, 100, 4090-4110.	3.3	165
3	Prediction of intestinal absorption: comparative assessment of gastroplus [®] and idea [®] . European Journal of Pharmaceutical Sciences, 2002, 17, 51-61.	4.0	159
4	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically based pharmacokinetic modeling approach. Journal of Pharmaceutical Sciences, 2011, 100, 4127-4157.	3.3	152
5	Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations. Clinical Pharmacokinetics, 1999, 36, 211-231.	3.5	141
6	Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling. Clinical Pharmacokinetics, 2006, 45, 1213-1226.	3.5	131
7	Applications of Physiologically Based Absorption Models in Drug Discovery and Development. Molecular Pharmaceutics, 2008, 5, 760-775.	4.6	107
8	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. Journal of Pharmaceutical Sciences, 2011, 100, 4074-4089.	3.3	105
9	An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery. Journal of Pharmaceutical Sciences, 2005, 94, 2327-2343.	3.3	100
10	Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants. Clinical Pharmacokinetics, 2011, 50, 613-623.	3.5	100
11	Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model. Drug Metabolism and Disposition, 2008, 36, 2434-2444.	3.3	92
12	Application of Full Physiological Models for Pharmaceutical Drug Candidate Selection and Extrapolation of Pharmacokinetics to Man. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 193-199.	2.5	91
13	Ethyl methanesulfonate toxicity in Viracept [®] —A comprehensive human risk assessment based on threshold data for genotoxicity. Toxicology Letters, 2009, 190, 317-329.	0.8	85
14	Prediction of Hepatic Metabolic Clearance. Clinical Pharmacokinetics, 2001, 40, 553-563.	3.5	79
15	Combining in Vitro and in Vivo Pharmacokinetic Data for Prediction of Hepatic Drug Clearance in Humans by Artificial Neural Networks and Multivariate Statistical Techniques. Journal of Medicinal Chemistry, 1999, 42, 5072-5076.	6.4	76
16	Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 585-611.	1.8	75
17	Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochemical Pharmacology, 2002, 64, 1637-1650.	4.4	74
18	Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans. Journal of Pharmaceutical Sciences, 2003, 92, 1990-2007.	3.3	67

#	ARTICLE	IF	CITATIONS
19	Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 1-15.	4.0	65
20	Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. <i>ATLA Alternatives To Laboratory Animals</i> , 2007, 35, 661-671.	1.0	59
21	Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 633-641.	2.4	57
22	Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine. <i>Molecular Pharmaceutics</i> , 2009, 6, 1716-1733.	4.6	56
23	PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4050-4073.	3.3	55
24	Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 23, 189-199.	4.0	52
25	Interspecies Pharmacokinetic Comparisons and Allometric Scaling of Napsagatran, a Low Molecular Weight Thrombin Inhibitor. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 85-91.	2.4	51
26	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentrationâ€time profiles in human from in vivo preclinical data by using the Wajima approach. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4111-4126.	3.3	51
27	Human clearance prediction: shifting the paradigm. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1039-1048.	3.3	44
28	Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3144-3156.	3.2	41
29	Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006, 63, 347-355.	4.3	37
30	Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. <i>Pharmaceutical Research</i> , 1996, 13, 97-101.	3.5	36
31	Animal Pharmacokinetics and Interspecies Scaling from Animals to Man of Lamifiban, a New Platelet Aggregation Inhibitor. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 573-577.	2.4	35
32	Interspecies Scaling of Interferon Disposition and Comparison of Allometric Scaling with Concentration-Time Transformations. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 1285-1290.	3.3	34
33	Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 73-85.	0.7	30
34	Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog. <i>Pharmaceutical Research</i> , 2012, 29, 1832-1842.	3.5	29
35	Translational PK/PD modeling to increase probability of success in drug discovery and early development. <i>Drug Discovery Today: Technologies</i> , 2016, 21-22, 27-34.	4.0	27
36	Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on <i>in vitro</i> Uptakeâ€Transport Data. <i>Chemistry and Biodiversity</i> , 2009, 6, 1975-1987.	2.1	18

#	ARTICLE	IF	CITATIONS
37	In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human. Toxicology Letters, 2009, 190, 303-309.	0.8	18
38	Importance of target-mediated drug disposition for small molecules. Drug Discovery Today, 2018, 23, 2023-2030.	6.4	15
39	Modelling of patient EMS exposure: Translating pharmacokinetics of EMS in vitro and in animals into patients. Toxicology Letters, 2009, 190, 310-316.	0.8	13
40	Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans. Clinical Pharmacokinetics, 2010, 49, 619-632.	3.5	10
41	Interspecies Scaling. , 2004, , 133-175.		3